NASDAQ:VNDA

Vanda Pharmaceuticals stock jumps premarket after FDA clears Bysanti — what to watch at the open

Vanda Pharmaceuticals shares jumped 33% to $7.68 in premarket trading Monday after the FDA approved its new antipsychotic pill, Bysanti, late Friday. The drug, milsaperidone, is bioequivalent to Vanda’s existing Fanapt and will be available commercially in the third quarter of 2026. Traders are watching whether the rally holds at the open and how Bysanti will compete in a crowded market.

23 February 2026

NASDAQ:VNDA·Pharmaceuticals·Stock Market

Healthcare stocks today: FDA decisions jolt biotechs as Wall Street shuts for New Year

Vanda Pharmaceuticals jumped 25% and Axsome rose 23% Wednesday after positive FDA decisions, while Corcept dropped 50% on a regulatory setback. The Health Care Select Sector SPDR Fund (XLV) slipped 0.6% as the S&P 500 fell 0.73%. U.S. markets were closed Thursday for New Year’s Day. Traders now await January macro data and managed-care earnings.

1 January 2026

NASDAQ:AXSM·NASDAQ:CORT·NASDAQ:VNDA

Nasdaq ends 2025 on a down note; markets closed today as jobs report, CPI loom

The Nasdaq Composite dropped 0.8% Wednesday to close 2025 at 23,241.99, while the S&P 500 lost 0.7% and the Dow fell 0.6%. U.S. markets are closed Thursday for New Year’s Day. Investors await the Jan. 9 jobs report, Jan. 13 inflation data, and the start of bank earnings for direction. Trading volume was below average, with tech and energy shares leading declines.

1 January 2026

Nasdaq·NASDAQ:MSFT·NASDAQ:VNDA·NYSE:EQT·Stock Market

Vanda (VNDA) stock jumps 28% after FDA approves Nereus motion-sickness drug

Vanda Pharmaceuticals shares rose 28.1% to $9.01 after the FDA approved Nereus to prevent motion-induced vomiting. Late-stage trials showed vomiting rates of 10%–20% on Nereus versus 38%–44% on placebo. Vanda plans to launch the drug in the coming months, with investors watching pricing and rollout against established over-the-counter competitors.

31 December 2025

NASDAQ:VNDA·Pharmaceuticals

S&P 500 edges down in thin year-end trade as jobless claims fall; Nike, Vanda jump

The Dow fell 114.33 points to 48,252.73, the S&P 500 lost 16.62 to 6,879.62, and the Nasdaq slipped 51.05 to 23,368.03 in thin year-end trading. U.S. jobless claims dropped to 199,000, sending Treasury yields higher. Nike gained after CEO Elliott Hill bought shares. Vanda Pharmaceuticals surged on FDA approval for its motion sickness drug.

31 December 2025

NASDAQ:VNDA·NYSE:NKE·Stock Market

Vanda Pharma stock jumps premarket after FDA approves Nereus, first new motion-sickness vomiting drug in decades

Vanda Pharmaceuticals shares rose about 18% in premarket trading after the FDA approved its motion-sickness drug Nereus (tradipitant). The company plans to launch the oral treatment in the coming months. The approval followed late-stage trials involving 681 patients. Shares closed at $7.03 Tuesday and were indicated around $8.30 early Wednesday.

31 December 2025

Healthcare News·NASDAQ:VNDA·Pharmaceuticals·Stock Market

Oil Prices Climb on Renewed U.S.-Iran Airstrikes, U.S. Stock Futures Rise
June 28, 2026, 8:36 PM EDT. Oil prices increased on Sunday as the U.S. and Iran exchanged airstrikes in the Persian Gulf, raising concerns over potential disruptions to the Strait of Hormuz, a crucial shipping route. U.S. stock-index futures edged higher amid escalating geopolitical tensions. The developments put energy markets on alert due to possible supply constraints from the strategic waterway.

Trump-era loan caps could open door for private lenders in grad school market

29 June 2026

July 1 federal loan caps slash Grad PLUS access, forcing many graduate and professional students to seek private loans; Sallie Mae projects up to 70% origination growth over several years, while SoFi reports record student-loan volume—investors now face a real-time test of how much demand shifts to private lenders as federal limits hit.

IREN Limited (NASDAQ:IREN) slides as Warriors badge faces AI revenue test

29 June 2026

IREN Limited (NASDAQ:IREN) plunged 21.3% to $47.21 over five straight down days despite announcing a record $50M+ annual Warriors jersey deal, as investors focused on the company’s not fully contracted $4.4B target ARR and high short interest at 19.74% of float, with Friday’s close near the lowest analyst target.

AbbVie stock run lifts pricing on $10.9 billion Apogee deal to six times cost

29 June 2026

AbbVie surged 17% since June 18 to a record $253.35, adding $65 billion in market value—six times its $10.9 billion Apogee buyout—driven by investor demand for long-term immunology growth despite near-term EPS dilution, as Skyrizi won expanded FDA approval and Humira sales fell.

Cisco stock selloff: Friday volume drives 90% of weekly drop before short U.S. market week

29 June 2026

Cisco plunged 4.37% to $113.77 on Friday, erasing $21 billion in market value on volume 2.3 times the recent average, as the stock tracked AI-linked peers instead of the Dow despite strong Q3 results and raised AI order targets; Friday’s close is the live reference for holders ahead of the July 4 holiday-shortened week.

NASDAQ:VNDA 31 December 2025 - 23 February 2026

Vanda Pharmaceuticals stock jumps premarket after FDA clears Bysanti — what to watch at the open

Healthcare stocks today: FDA decisions jolt biotechs as Wall Street shuts for New Year

Nasdaq ends 2025 on a down note; markets closed today as jobs report, CPI loom

Vanda (VNDA) stock jumps 28% after FDA approves Nereus motion-sickness drug

S&P 500 edges down in thin year-end trade as jobless claims fall; Nike, Vanda jump

Vanda Pharma stock jumps premarket after FDA approves Nereus, first new motion-sickness vomiting drug in decades

Stock Market Today

Latest articles

Trump-era loan caps could open door for private lenders in grad school market

IREN Limited (NASDAQ:IREN) slides as Warriors badge faces AI revenue test

AbbVie stock run lifts pricing on $10.9 billion Apogee deal to six times cost

Cisco stock selloff: Friday volume drives 90% of weekly drop before short U.S. market week

Latest Video